Biopharmaceutical Executive Sells Company Shares Worth Approximately $28 Million

Centessa Pharmaceuticals plc (NASDAQ: CNTA) announced on March 13 that Gregory M. Winhoff, its Chief Business Officer, sold a portion of his holdings in open-market transactions under a pre-established Rule 10b5-1 trading plan. In two separate sales, Winhoff disposed of common stock valued at approximately $19.3 million (about ₩2.8 billion), reducing his direct stake to 65,925 shares.

The company’s board recently appointed Mario Alberto Accardi as Chief Executive Officer, effective January 1, 2026, formalizing a strategic shift to focus on orexin receptor agonists.

Headquartered in Altrincham, United Kingdom, Centessa is a clinical-stage pharmaceutical company developing a pipeline centered on orexin receptor 2 agonists for sleep and wake disorders—its lead candidate, ORX750, targets narcolepsy and related conditions.